

April 27, 2022



Khiron to Host YE and Fourth Quarter 2021 Conference Call on May 2, 2022

TORONTO, April 27, 2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, today announces that it will host a conference call on Monday, May 2nd, 2022 at 10:00 a.m. Eastern Time to discuss its financial results for year ended and quarter ended December 31, 2021. The Company will press release its financial results prior to the conference call. These filings will be available for review on the Company's SEDAR profile at www.sedar.com



Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Company's YE and Fourth Quarter 2021 Conference Call, followed by a Q&A session.

Conference Call Date: May 2nd, 2022

Time 10:00 a.m. Eastern time

Toll-free dial-in number: 1-888-664-6383

International dial-in number: 1-416-764-8650

Please call the conference telephone number 5-10 minutes prior to the start time. An

operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Khiron Investor Relations team at (647) 556-5750

A telephonic replay of the conference call will also be available after 8:00 p.m. Eastern time on the same day through June 2nd, 2022.

Toll-free replay number: 1-888-390-0541

International replay number: 1-416-764-8677

Replay ID: 935848

About Khiron Life Sciences Corp.

Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca

Linkedin <https://www.linkedin.com/company/khiron-life-sciences-corp/>

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

View original content to download multimedia <https://www.prnewswire.com/news-releases/khiron-to-host-ye-and-fourth-quarter-2021-conference-call-on-may-2-2022-301534717.html>

SOURCE Khiron Life Sciences Corp.